| Cat.No. | Name | Information |
|---|---|---|
| M1881 | Tozasertib | Tozasertib (VX-680, MK-0457) is a potent and selective pan-Aurora kinase inhibitor active against all Bcr/Abl proteins. |
| M1752 | Aliertib (MLN 8237) | Alisertib (MLN8237) is a second-generation, orally bioavailable, highly selective Aurora kinase A inhibitor with IC50 of 61 nM. |
| M1663 | AZD1152-HQPA | AZD1152-HQPA (Barasertib) is a highly potent and selective inhibitor of Aurora with Ki values of 0.36 and 1369 nM for Aurora B and Aurora A respectively. |
| M1877 | ZM447439 | ZM447439 is the first Aurora family kinase inhibitor with IC50 of 50 nM for Aurora B kinase. |
| M1769 | PHA-739358 (Danusertib) | PHA-739358 (Danusertib) is a small molecule with low nanomolar activity against all aurora kinases (AKs) with IC50 value of 13 nM for aurora-A and 79 nM for aurora-B respectively. |
| M1751 | MLN8054 | MLN8054 is an orally bioavailable, highly selective small molecule inhibitor of Aurora with IC50s of 0.004uM and 0.172uM. for Aurora A and Aurora B. |
| M1706 | ENMD-2076 | ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor. |
| M1694 | CYC116 | CYC116 is a potent, small molecule inhibitor of Aurora A, B and C with IC50 value of 44, 19 and 65 nM respectively. CYC-116 also inhibits VEGFR2, Src, Lck AND FLT3 with with Kis of 44, 82, 280, 44 nM, respectively. CYC-116 may have broad-spectrum antitumor activity. |
| M1691 | CCT-129202 | CCT129202 is an Aurora kinase inhibitor with IC50 of 0.042 ± 0.022, 0.198 ± 0.05, and 0.227 ± 0.064 μmol/L for Aurora A, Aurora B, and Aurora C, respectively. |
| M1655 | AT9283 | AT9283 is a potent inhibitor of several protein kinases, including Aurora A, Aurora B, Janus kinase 2 (JAK2), JAK3, and ABL. |
| M55926 | Phthalazinone pyrazole | Phthalazinone pyrazole is a potent, selective, and orally active inhibitor of Aurora-A kinase with an IC50 of 0.031 μM. |
| M41412 | Aurora Kinases-IN-4 | Aurora Kinases-IN-4 is a covalent and ATP competitive aurora kinase A inhibitor (IC50: 1.7 nM). |
| M38914 | Derrone | Derrone, a prenylated isoflavones, is an Aurora kinase inhibitor, with IC50 values of 6 and 22.3 μM against Aurora B and Aurora A, respectively. Derrone shows anti-tumor activity. |
| M31003 | CD532 hydrochloride | CD532 hydrochloride is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 hydrochloride has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 hydrochloride also can directly interact with AURKA and induces a global conformational shift. CD532 hydrochloride can be used for the research of cancer. |
| M29927 | Aurora kinase inhibitor-2 | Aurora kinase inhibitor-2 is a selective and ATP-competitive Aurora kinase inhibitor with IC50s of 310 nM and 240 nM for Aurora A and Aurora B, respectively. |
| M29436 | AAPK-25 | AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3Ser10 phosphorylation and followed by a surge in apoptosis. AAPK-25 targets Aurora-A, -B, and -C with Kd values ranging from 23-289 nM, as well as PLK-1, -2, and -3 with Kd values ranging from 55-456 nM. |
| M29284 | Aurora kinase inhibitor-8 | Aurora kinase inhibitor-8 is a highly selective inhibitor of the Aurora kinases. |
| M28750 | CD532 | CD532 is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 also can directly interact with AURKA and induces a global conformational shift. CD532 can be used for the research of cancer. |
| M28425 | AKI603 | AKI603 is an inhibitor of Aurora kinase A (AurA), with an IC50 of 12.3 nM. AKI603 is developed to overcome resistance mediated by BCR-ABL-T315I mutation. AKI603 exhibits strong anti-proliferative activity in leukemic cells. |
| M27784 | SCH-1473759 hydrochloride | SCH-1473759 hydrochloride is an aurora inhibitor with IC50s of 4 and 13 nM for aurora A and B, respectively. |
| M20733 | SP-96 | SP-146 is a potent, selective and non-ATP-competitive inhibitor of Aurora B with IC50 of 0.316 nM. SP-146 can be used for the research of triple negative breast cancer (TNBC). |
| M20284 | WAY-661516 | WAY-661516 is a Aurora kinase A inhibitor. |
| M20251 | WAY-638641 | WAY-638641 is a Aurora kinase A inhibitor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
